all

The digital tool entitled "NAFCS Digital PDF scoring tool" is attached for your use.  The digital calculator is based on the article published in the Journal of Clinical Lipidology. Hegele et al. wrote the publication utilizing the RAND/UCLA modified Delphi process. The NAFCS manuscript may potentially help distinguish FCS from MCS, another genetic form of severe hypertriglyceridemia. Additionally, it may be used to help confer a clinical diagnosis of FCS in the event of an indeterminate genetic test, or to identify appropriate candidates for genetic testing.¹

The National Lipid Association (NLA), in collaboration with the American Society for Preventive Cardiology (ASPC), has released a Joint Expert Clinical Consensus providing new guidance on the recognition and management of persistent chylomicronemia — a severe and often misunderstood form of hypertriglyceridemia. The full paper is now published in the Journal of Clinical Lipidology and available here.

Extreme hypertriglyceridemia, defined as triglyceride (TG) levels ≥1000 mg/dL, is almost always indicative of chylomicronemia. The current diagnostic approach categorizes individuals with chylomicronemia into familial chylomicronemia syndrome (FCS; prevalence 1–10 per million), caused by the biallelic combination of pathogenic variants that impair the lipolytic action of lipoprotein lipase (LPL), or multifactorial chylomicronemia syndrome (MCS, 1 in 500). A pragmatic framework should emphasize the severity of the phenotype and the risk of complications.